Seeking Solutions for Brain Tumors
“We’re not in the top ranking among [hospitals conducting] clinical trials, but when you look at enrollment we are at the top of the list,” he says. “We are offering a high volume of cases, and the more you do, the
better you are; like in many disciplines, it relates to better outcomes and
Researching a prospective “tumor vaccine is something we are pursuing,” he says. In developing programs, whether telestroke or brain tumor research, “having clinical focus is absolutely critical,” Pomeroy says.
Funding sources for the Barrow programs include the National Institutes of Health, focusing on areas ranging from basic science research, advanced diagnostics, or therapeutic innovations. “I think increasing our clinical volume will be a substantial indicator of our success,” Pomeroy says.
This article appears in the September 2011 issue of HealthLeaders magazine.
Joe Cantlupe is a senior editor with HealthLeaders Media Online.
- Providers Lag as Consumers Set Agenda
- Look Beyond Nurse-Patient Ratios
- Esther Dyson Launches Population Health Challenge
- Reform Puts Vise Grips on Physicians
- Crisis Spurs Healthcare Payment Reform in Arkansas
- Hospital Groups Back NQF Report on Patient Sociodemographics
- ICD-10 Delay Alters Provider, Vendor Prep
- NPP Demand Rising Under Value-Based Care Models
- Medicare Opt-Out a Viable Physician Strategy
- Reduce Readmissions by Activating Patients to Do 'Self-Care'